Form 4: NextCure Director Ellen Feigal Acquires 18,700 Stock Options

NextCure, Inc. Director Ellen Feigal reported the acquisition of 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

Summary

• Ellen Feigal, a Director of NextCure, Inc. (NXTC), acquired 18,700 stock options.
• The stock options have an exercise price of $0.47 per share.
• The transaction date for this acquisition was June 20, 2025.
• These options are scheduled to vest in full on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• The options have an expiration date of June 19, 2035.
• Following this reported transaction, Ms. Feigal beneficially owns 18,700 derivative securities directly.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally a positive signal of alignment and confidence, though it represents a routine compensation event rather than a significant strategic move.

Positives

• The acquisition of stock options by a director aligns management's interests with those of shareholders, potentially signaling confidence in the company's future performance.

Risks

• The value of the stock options is dependent on the future stock price of NextCure, Inc. (NXTC) exceeding the exercise price of $0.47 per share.

Future Outlook

The acquired stock options are set to vest by June 20, 2026, or earlier, and have an expiration date of June 19, 2035, indicating a long-term incentive for the director.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity compensation, common across publicly traded companies, and does not provide broader industry trend insights.

Related Party Transactions

• The acquisition of stock options by Ellen Feigal, a director, from NextCure, Inc. is a related party transaction as it involves a company insider receiving equity compensation.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive indicator of management's belief in the company's future prospects and alignment with shareholder value creation.

Next Steps

• The stock options will vest in accordance with the specified schedule (earlier of June 20, 2026, or the 2026 Annual Meeting of Stockholders).
• Ellen Feigal may choose to exercise the options at any time after vesting and before the expiration date of June 19, 2035.

Key Dates

Keywords

NextCure, NXTC, SEC Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Director, Equity Compensation